[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":611},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,42,66,91,120,149,173,197,223,247,267,293,310,327,350,370,390,423,445,466,492,519,546,567,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100645130","phase-4-177lu-psma-617-combined-with-darolutamide-in-neoadjuvant-treatment-of-high-risk-localized-prostate-cancer-a-prospective-single-arm-multi-center-clinical-trial-100645130",false,"NCT07677566","177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial","IUNU-PC-123","Inclusion Criteria:\n\n1. Patients must be ≥ 18 and ≤75 years of age\n2. All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy\n3. All patients meet at least one of the following criteria： multi-parameter MRI or PSMA PET \u002F CT shows clinical staging of primary tumor ≥ T2c； Gleason score of primary tumor ≥ 8； prostate specific antigen (PSA) ≥20 ng\u002Fml； Radiographic assessment of regional lymph node metastases (N1)\n4. Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1\n5. Primary lesion SUVmax ≥ 20.0 as assessed by PSMA-PET examination.\n6. Adequate organ function: Complete Blood Count: White blood cell count (WBC) ≥ 3.0 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 9 g\u002FdL. Renal Function: Serum creatinine ≤ 2 × ULN. Liver Function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin (TBIL) ≤ 1.5 × ULN. Coagulation Function: International normalized ratio (INR) \\\u003C 1.5.\n7. Voluntary Participation: Participants must voluntarily agree to participate and sign the informed consent form (ICF), indicating their understanding of the purpose of the study and the required procedures, as well as their willingness to participate in the research. Participants must be willing to comply with the prohibitions and restrictions outlined in the study protocol.\n8. Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment\n\nExclusion Criteria:\n\n1. Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible\n2. Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: prostate specific antigen (PSA) \\\u003C20 ng\u002FmL multiparameter MRI or PSMA PET \u002F CT shows clinical staging of primary tumor \\\u003C T3, Gleason score of primary tumor \\\u003C 8\n3. Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases (any M1）\n4. Primary lesion SUVmax \\\u003C 20.0 as assessed by PSMA-PET examination.\n5. Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy\n6. Patients with severe or uncontrolled concurrent infections\n7. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration\n8. Uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection\n9. Patients with a history of other malignancies within the past 5 years, except for prostate cancer, are not eligible; however, cured basal cell carcinoma or squamous cell carcinoma of the skin may be eligible\n10. Patients with mental illness, mental disability, or inability to provide informed consent","MALE","18 Years","75 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are:\n\nDoes this combination treatment improve the pathological complete response rate (pCR)? What is the minimal residual disease (MRD) rate in these patients? What are the safety profiles and any adverse effects associated with this treatment? Researchers will compare the combination of darolutamide and 177Lu-PSMA-617 to a placebo to see if the combination is effective in treating high-risk localized prostate cancer.\n\nParticipants will:\n\nReceive either darolutamide combined with 177Lu-PSMA-617 or a placebo every day for 12 weeks.\n\nVisit the clinic every 6 weeks for checkups and tests. Keep a diary of their symptoms and any side effects experienced during the treatment.\n\nUndergo imaging tests, including prostate MRI and PSMA PET\u002FCT, before surgery and during follow-up.",[28,29],"Prostate Cancer","Prostate Cancer Patients","NOT_YET_RECRUITING","2026-06-24",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":33,"type":22},{"date":37,"type":22},"2028-12-31",{"name":39,"class":40},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100588828","early-phase-1-universal-anti-cd70-car-t-cht101-cell-therapy-for-relapsed-refractory-systemic-lupus-erythematosus-100588828","NCT06946485","Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus","A Clinical Study of the Safety and Efficacy of Universal Anti-CD70 CAR-T (CHT101) for the Treatment of Relapsed and Refractory Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Meet the 2019 EULAR\u002FACR classification criteria for systemic lupus erythematosus (SLE).\n2. SLEDAI-2000 score \\>6.\n3. Have at least one BILAG-2004 Grade A or two Grade B organ domain scores, or both.\n4. Failure to respond to conventional therapy or disease relapse after remission. Conventional therapy: Glucocorticoids (≥1 mg\u002Fkg\u002Fday) combined with cyclophosphamide and ≥1 of the following immunosuppressants for \\>6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine A, and\u002For biologics (e.g., rituximab, belimumab, telitacicept).\n5. Aged 18-65 years; both genders eligible.\n6. Adequate organ function:Bone marrow function: White blood cell count ≥3×10⁹\u002FL. Absolute neutrophil count ≥1×10⁹\u002FL (without colony-stimulating factor therapy within 2 weeks prior to testing). Hemoglobin ≥60 g\u002FL; Liver function: Alanine aminotransferase (ALT) ≤3×upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤3×ULN. Total bilirubin (TBIL) ≤1.5×ULN (except Gilbert's syndrome, TBIL ≤3.0×ULN); Renal function: Creatinine clearance (CrCl) ≥60 mL\u002Fmin (calculated by Cockcroft-Gault formula); Coagulation: International normalized ratio (INR) ≤1.5×ULN. Prothrombin time (PT) ≤1.5×ULN; Cardiac function: Hemodynamic stability with left ventricular ejection fraction (LVEF) ≥55%.\n7. Agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication. Females of childbearing potential must have a negative serum HCG test within 7 days prior to enrollment and must not be lactating.\n8. Voluntarily participate in the study, provide written informed consent, and demonstrate good compliance with follow-up.\n\nExclusion Criteria:\n\n1. Presence of neuropsychiatric lupus (NPSLE).\n2. History of thrombotic thrombocytopenic purpura (TTP) or thrombotic microangiopathy (TMA).\n3. History of severe drug allergies or hypersensitivity.\n4. Active or suspected uncontrolled infections requiring treatment (including fungal, bacterial, viral, or other pathogens).\n5. Central nervous system disorders caused by autoimmune diseases (ADs) or non-ADs.\n6. Severe cardiac diseases.\n7. Congenital immunoglobulin deficiency.\n8. History of malignancy (except non-melanoma skin cancer, in situ cervical\u002Fbladder\u002Fbreast\u002Fthyroid carcinoma with disease-free survival \\>5 years).\n9. End-stage renal failure.\n10. Participants meeting any of the following: Hepatitis B surface antigen (HBsAg)-positive or hepatitis B core antibody (HBcAb)-positive with detectable HBV DNA; Hepatitis C virus (HCV) antibody-positive with detectable HCV RNA; HIV antibody-positive; Syphilis-positive (RPR and TPHA positive, or TPHA positive with RPR reconfirmed positive after 4 weeks).\n11. Psychiatric disorders or severe cognitive impairment.\n12. Participation in other clinical trials within 3 months prior to enrollment.\n13. Pregnant women or those planning pregnancy.\n14. Other conditions deemed by the investigator to preclude study participation.","ALL","65 Years",{"count":52,"type":22},15,[54],"EARLY_PHASE1","This investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.",[57],"Systemic Lupus Erythematosus (SLE)","RECRUITING",{"date":60,"type":34},"2026-06-29",{"date":62,"type":34},"2025-04-02",{"date":64,"type":22},"2027-03",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":50,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100590545","phase-3-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-with-stanford-type-a-aortic-dissection-100590545","NCT06968806","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with Stanford Type A aortic dissection confirmed by imaging and scheduled for emergency surgery.\n\nAged between 18 and 65 years.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Patients who are unable to eat independently or require prolonged fasting.\n\nHistory of malignant tumors.\n\nBody weight \\\u003C50 kg.\n\nTraumatic aortic dissection.\n\nPatients with Marfan syndrome.\n\nUnstable vital signs requiring preoperative mechanical support or resuscitation (e.g., IABP \\[Intra-Aortic Balloon Pump\\], ECMO \\[Extracorporeal Membrane Oxygenation\\], LVAD \\[Left Ventricular Assist Device\\])\n\nPatients requiring preoperative endotracheal intubation.\n\nConsciousness impairment, central nervous system dysfunction, or evidence of cerebral malperfusion syndrome upon admission.\n\nPreoperative hematemesis, melena, fresh blood in stool, or symptoms of bowel dilation.\n\nClear evidence of limb malperfusion before surgery.\n\nPresence of organ malperfusion syndrome.\n\nPatients requiring interventional procedures to relieve organ malperfusion before surgery.\n\nHistory of gastrointestinal ulcers or chronic gastrointestinal inflammatory diseases.\n\nHistory of dialysis or renal insufficiency before admission.\n\nHistory of liver disease.\n\nAllergy to ketorolac tromethamine, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n\nChronic inflammatory diseases, autoimmune diseases, or long-term use of steroids or NSAIDs for other reasons.\n\nAbsence of cerebral perfusion during deep hypothermic circulatory arrest.\n\nHistory of major surgery or acute myocardial infarction within 90 days.\n\nHistory of cardiac or major vascular surgery.\n\nPregnant or lactating women.\n\nPatients who refuse to participate in this clinical trial or decline to sign the informed consent form.\n\nAny other conditions deemed unsuitable for participation by the investigator.",{"count":74,"type":22},360,[76],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \\[IM\\] preoperatively and 30 mg twice daily \\[BID\\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.",[79,80],"Aortic Dissection","Inflammation",[80,79,82],"Ketorolac","2026-06-19",{"date":85,"type":34},"2026-06-23",{"date":87,"type":34},"2025-10-27",{"date":89,"type":22},"2028-09-01",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":19,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100644191","phase-1-a-study-of-metformin-to-improve-cardiac-function-after-lvad-implantation-100644191","NCT07666698","A Study of Metformin to Improve Cardiac Function After LVAD Implantation","Study on the Effect of Metformin in Improving Cardiac Function After Implantation of Left Ventricular Assist Devices","Inclusion Criteria:\n\n* Age 18-75 years\n* Receiving continuous-flow LVADs, such as HeartMate 3, HVAD, Core-Heart 6, Brio-Heart\n* Presence of insulin resistance\n* HbA1c ≤ 6.5%\n\nExclusion Criteria:\n\n* Diagnosed type 1 diabetes mellitus, or type 2 diabetes mellitus with HbA1c \\> 6.5% (patients with prior type 2 diabetes who are currently off therapy and have HbA1c ≤ 6.5% may be enrolled; such patients may still have insulin resistance but have achieved glycemic control)\n* History of diagnosed diabetic ketoacidosis or hyperosmolar hyperglycemic state\n* Currently using any glucose-lowering medications (including insulin, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, etc.)\n* History of diagnosed polycystic ovary syndrome (PCOS) and currently undergoing treatment\n* Estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m² (CKD-EPI equation)\n* History of acute kidney injury (KDIGO criteria) with incomplete renal recovery\n* Receiving any form of renal replacement therapy (hemodialysis, peritoneal dialysis)\n* Post-kidney transplantation or awaiting kidney transplantation\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3× the upper limit of normal, total bilirubin \\> 2× upper limit of normal, or Child-Pugh class B or C cirrhosis\n* Active viral hepatitis\n* History of alcoholic liver disease or drug-induced liver injury currently in the active phase\n* Concurrent right ventricular assist device (RVAD) or total artificial heart implantation\n* LVAD-related complications requiring surgical intervention within 30 days postoperatively, including but not limited to: pump thrombosis requiring LVAD exchange or thrombolysis, driveline infection requiring debridement or replacement, hemorrhagic complications requiring re-sternotomy, device malfunction requiring urgent intervention\n* Acute kidney injury requiring ongoing renal replacement therapy (CRRT) within 30 days postoperatively\n* Preoperative severe right heart failure (on echocardiography: right ventricular fractional area change \\\u003C 35%, or tricuspid annular plane systolic excursion \\\u003C 14 mm; or right heart catheterization showing central venous pressure \\> 15 mmHg and cardiac index \\\u003C 2.0 L\u002Fmin\u002Fm²)\n* Preoperative severe pulmonary arterial hypertension (mean pulmonary arterial pressure ≥ 40 mmHg and pulmonary vascular resistance ≥ 4 Wood units)\n* Within 30 days postoperatively, occurrence of severe low cardiac output syndrome requiring extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) support\n* Significant prosthetic valve dysfunction or severe prosthetic valve infectious endocarditis\n* Severe unrepaired valvular disease\n* Active systemic infection or sepsis requiring ongoing intravenous antibiotics or antifungal therapy\n* Active infectious endocarditis (modified Duke criteria) or high clinical suspicion\n* Human immunodeficiency virus (HIV) infection with CD4 count \\\u003C 200\u002FμL or not on regular antiretroviral therapy\n* Active tuberculosis or non-tuberculous mycobacterial infection\n* Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection\n* Known active inflammatory diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease) currently requiring immunosuppressive therapy\n* Platelet count \\\u003C 50 × 10⁹\u002FL, hemoglobin \\\u003C 80 g\u002FL, international normalized ratio (INR) \\> 3.0 and not reversible (unless on warfarin with INR within the target range)\n* Known bleeding disorders (e.g., hemophilia, von Willebrand disease, acquired von Willebrand syndrome)\n* Malignancy diagnosed within the past 5 years (except for cured thyroid cancer, breast cancer, lung cancer, cervical cancer, etc.) and currently receiving chemotherapy, radiotherapy, or targeted therapy\n* Prior recipients of heart transplantation or other organ transplants\n* Patients awaiting heart transplantation with an anticipated waiting time of less than 3 months\n* Pregnant or lactating women\n* Reproductive-age women who are capable of conceiving but refuse to use effective contraception during the study period (including surgical sterilization, intrauterine device, oral contraceptives, condoms, etc.)\n* Women planning pregnancy during the study\n* Known allergy to metformin or any drug excipient\n* Known history of lactic acidosis\n* Currently using medications that may significantly increase the risk of lactic acidosis, including but not limited to: carbonic anhydrase inhibitors (topiramate, acetazolamide), antiretroviral drugs (especially nucleoside reverse transcriptase inhibitors), certain chemotherapeutic agents (cisplatin)\n* Currently using medications that may affect glycemic control or insulin sensitivity and that cannot be stopped or substituted during the study, including but not limited to: systemic glucocorticoids (prednisone-equivalent dose \\> 10 mg\u002Fday for \\> 2 weeks), high-dose thiazide diuretics (hydrochlorothiazide \\> 50 mg\u002Fday), atypical antipsychotics (olanzapine, clozapine, etc.), immunosuppressants (tacrolimus, cyclosporine, etc.)\n* Unable to complete 12-month follow-up\n* Known psychiatric disorders or cognitive impairment that may affect informed consent validity or study compliance\n* History of drug or alcohol abuse (within the past year)\n* Concurrent participation in another clinical trial\n* Any other circumstance, as determined by the investigator, that would render the subject unsuitable for enrollment (including but not limited to social, psychological, or geographic factors)",{"count":99,"type":22},108,[101,102],"PHASE1","PHASE2","This study investigates whether metformin, compared with placebo, improves cardiac function in patients after Left Ventricular Assist Device (LVAD) implantation. Metformin is a widely used oral medication for type 2 diabetes, but emerging evidence suggests it may have beneficial effects on cardiac metabolism and function independent of its glucose-lowering effects. This is a prospective, multicenter, randomized, double-blind, placebo-controlled trial. A total of 108patients undergoing LVAD implantation will be enrolled from 5 centers in China. Eligible participants will be randomly assigned in a 1:1 ratio to receive either metformin or placebo for 12 months.\n\nThe primary outcome is the incidence of Full Responder at 12 months post-implantation. A Full Responder is defined as meeting all of the following four criteria: (1) left ventricular ejection fraction (LVEF) ≥40% and left ventricular end-diastolic diameter (LVEDD) ≤6.0 cm (Utah-Inova Responder criteria); (2) soluble ST2 (sST2) ≤100 ng\u002FmL at both 6 months and 12 months post-implantation; (3) absolute value of left ventricular global longitudinal strain (GLS) ≥12% at 12 months post-implantation.\n\nSecondary outcomes include clinical events, cardiac function status, blood biomarker results, global functional status and quality of life, medication safety, and exploratory measures. Clinical events assessed up to 24 months post-implantation include: heart failure rehospitalization rate, all-cause mortality, LVAD explantation rate, cardiovascular mortality, major bleeding, cardiac structural damage, thromboembolic events, systemic inflammatory dissemination, sepsis, and other serious adverse events.\n\nCardiac function status is evaluated by echocardiographic parameters (LVEF, LVEDD, GLS) and hemodynamic measures. Blood biomarkers include sST2, NT-proBNP, cardiac troponin, and inflammatory cytokines. Global functional status and quality of life are measured using the 6-minute walk test (6MWT), peak oxygen consumption (VO₂max), and the Kansas City Cardiomyopathy Questionnaire (KCCQ). Safety outcomes include the incidence and severity of adverse events, serious adverse events, and adverse events of special interest. Exploratory outcomes include pre-implantation right ventricular myocardial biopsy (obtained only when clinically indicated for temporary pacemaker lead placement) to assess insulin receptor substrate (IRS)\u002FAkt phosphorylation, G6PD activity, NADPH\u002FNADP⁺ ratio, and oxidative stress markers (malondialdehyde, 4-hydroxynonenal).\n\nThe study aims to provide evidence on whether adjunctive metformin therapy can improve post-LVAD cardiac outcomes and reduce adverse clinical events.",[105,106],"Heart Failure","Left Ventricular Assist Device",[108,109,110,111,112],"Metformin","Cardiac Function","LVAD","Randomized Controlled Trial","Full Responder","2026-06-18",{"date":31,"type":34},{"date":116,"type":22},"2026-07",{"date":118,"type":22},"2029-09",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":49,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":41},"100641111","the-cognitive-protective-effect-of-vr-based-cognitive-training-in-type-2-diabetes-patients-with-mild-cognitive-impairment-100641111","NCT07650318","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment：A Prospective, Randomized, Open-Label, Parallel-Group Pilot Study","Inclusion Criteria:\n\n1. Aged 45-80 years; gender is not restricted;\n2. Participants must meet the diagnostic criteria for diabetes outlined in the \\*Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)\\*, namely: patients exhibit typical symptoms of diabetes and meet one of the following conditions: 1) HbA1c ≥ 6.5%; 2) Fasting blood glucose ≥7.0 mmol\u002FL. Fasting is defined as no caloric intake for at least 8 hours; 3) 2-hour postprandial blood glucose ≥11.1 mmol\u002FL following an oral glucose tolerance test; 4) Random blood glucose ≥11.1 mmol\u002FL;\n3. Stable glycemic control regimen for 3 months or longer;\n4. Completed a systematic neuropsychological assessment and met the MCI diagnostic criteria outlined in the 2018 American Academy of Neurology Guidelines for Mild Cognitive Impairment, satisfying the following conditions: 1) The patient or a caregiver subjectively perceives a decline in cognitive function; 2) Assessment results indicate impairment in one or more cognitive domains; 3) There is mild impairment in complex instrumental activities of daily living, but the patient maintains independence in basic activities of daily living; 4) Does not yet meet the diagnostic criteria for dementia;\n5. Has an educational level of elementary school or higher and is able to cooperate in completing the assessment, VR training, and various examinations;\n6. Cooperate in undergoing magnetic resonance imaging (MRI) examinations;\n7. Voluntarily participates in this study, signs an informed consent form, and is able to comply with the study protocol requirements to complete follow-up.\n\nExclusion Criteria:\n\n1. Suffering from other dementia-related neurological disorders (such as Alzheimer's disease, Parkinson's disease, etc.) or severe mental illness;\n2. History of central nervous system disorders, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc.;\n3. Severe sinusitis, space-occupying lesions in the nasopharynx, or congenital disorders affecting the sense of smell,or a history of trauma;\n4. Glaucoma, severe dry eye syndrome, uncorrected strabismus, severe diabetic retinopathy,or severe motion sickness, making the user unable to tolerate VR devices;\n5. History of acute diabetic complications within the past 3 months (diabetic ketoacidosis, hyperglycemic hyperosmolar state, severe hypoglycemia, etc.);\n6. Severe impairment of vital organ function, including cardiac, hepatic, or renal dysfunction;\n7. Pregnant or breastfeeding women, or women planning to become pregnant during the study;\n8. Contraindications for MRI scans, such as the presence of metallic prostheses, pacemakers, cochlear implants, or other metallic implants, or claustrophobia;\n9. Participation in other clinical trials currently or within the past 3 months;\n10. Known or suspected history of allergy to study-related materials;\n11. Currently taking medications intended to improve cognitive function.","45 Years","80 Years",{"count":130,"type":22},40,[132],"NA","A single-center, prospective, open-label, parallel-group randomized controlled trial is conducted to investigate the cognitive-protective efficacy of a novel, diabetes-specific virtual reality (VR)-based cognitive training system integrated with diet management modules, relative to frequency- and duration-matched traditional paper-and-pencil cognitive training, in adults aged 45-80 years with T2DM and amnestic\u002Fmixed mild cognitive impairment (MCI). A total of 40 eligible participants are randomly assigned 1:1 to either the intervention group (16 weeks of individualized VR training with dynamic difficulty, 2 sessions\u002Fweek, 30-60 minutes\u002Fsession) or the active control group (standardized paper-and-pencil cognitive tasks). All participants maintain stable glucose-lowering regimens for ≥3 months and receive standardized weekly diabetes health education. The primary endpoint is the between-group difference in the change in MoCA total score from baseline to the 16-week follow-up. Secondary endpoints include changes in individual cognitive domains (memory, executive function, attention, processing speed), olfactory threshold\u002Fidentification\u002Frecall, brain structural volumes and resting-state functional connectivity (assessed via 3.0T fMRI), glycemic control (HbA1c, fasting\u002Fpostprandial glucose), lipid profile, body composition, sleep quality, anxiety and depressive symptoms, and diabetes self-management behaviors. The safety and participant adherence to the VR intervention are also systematically monitored.",[135,136],"Type 2 Diabetes Mellitus (T2DM)","Mild Cognitive Impairment (MCI)",[138,139,140,141],"Cognition","Cognitive training","Functional MRI","Virtual reality (VR) technology","2026-06-16",{"date":113,"type":34},{"date":145,"type":34},"2026-06-01",{"date":147,"type":22},"2028-06-01",{"name":39,"class":40},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100642273","effects-of-different-secukinumab-maintenance-regimens-on-long-term-outcomes-in-patients-with-psoriasis-100642273","NCT07642544","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.\n* Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.\n* Achieved PASI 75 response at the end of the induction period.\n* Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.\n* Complete electronic medical record data available for extraction.\n\nExclusion Criteria:\n\n* Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.\n* Irregular maintenance treatment pattern, or substantial missing data.\n* Use of other targeted biologic agents or small molecule drugs during the maintenance period.\n* Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.\n* Participation in other interventional clinical trials that may confound efficacy assessment.",{"count":157,"type":22},120,"OBSERVATIONAL","To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.",[161,162],"Psoriasis","Psoriasis (PsO)",[164,165],"psoriasis","secukinumab","2026-06-09",{"date":168,"type":34},"2026-06-11",{"date":145,"type":22},{"date":171,"type":22},"2027-03-01",{"name":39,"class":40},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":49,"minAge":180,"maxAge":19,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100642760","transcutaneous-auricular-vagus-nerve-stimulation-in-type-2-diabetes-with-mild-cognitive-impairment-100642760","NCT07642518","Transcutaneous Auricular Vagus Nerve Stimulation in Type 2 Diabetes With Mild Cognitive Impairment","Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Type 2 Diabetes and Mild Cognitive Impairment: A Single-Center, Randomized, Double-Blind, Sham-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus\n2. Meets criteria for mild cognitive impairment\n3. Aged 40 to 75 years, with no gender restrictions\n4. HbA1c levels between 6.5% and 9.0%\n5. At least 6 years of formal education\n6. Able to cooperate with and complete all cognitive and functional assessments\n7. Right-handed\n8. Voluntary provision of written informed consent\n\nExclusion Criteria:\n\n1. Concomitant use of GLP-1 receptor agonists, Alzheimer's disease medications, anti-Parkinson's medications, antiepileptic drugs, or antipsychotic drugs within 3 months prior to screening\n2. Presence of dementia-related neurological disorders; current or history of clinically significant psychiatric disorders within the past 2 years (e.g., schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders)\n3. CNS diseases, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc\n4. Severe sinusitis, nasal and sinus polyps, space-occupying lesions such as skull base or nasopharyngeal tumors; congenital diseases or history of trauma of the nose, maxillofacial region, or skull base that affect olfactory function; presence of upper respiratory tract infection symptoms (e.g., nasal congestion, rhinorrhea, fever) on the day of the MRI scan\n5. Acute complications of diabetes, including diabetic ketoacidosis, hyperglycemic hyperosmolar state, hypoglycemic coma, etc\n6. Severe impairment of major organ function (e.g., heart, liver, kidneys), including any of the following: ALT and\u002For AST \\> 3×ULN. eGFR \\\u003C 45 mL\u002Fmin\u002F1.72 m² (CKD-EPI). History of unstable angina, myocardial infarction, or NYHA Class II or higher heart failure within 3 months prior to screening\n7. Concurrent major illnesses, such as active or untreated malignancies, or malignancies in clinical remission for less than 5 years.\n8. Contraindications for MRI scans (e.g., implanted metallic prostheses, claustrophobia); presence of cardiac pacemakers or other implantable medical devices; severe infection or ulceration of the auricular skin\n9. Pregnant or lactating women\n10. History of alcohol abuse, defined as an average weekly alcohol consumption exceeding 21 units for males and 14 units for females (1 unit = 360 mL of beer, 150 mL of wine, or 45 mL of distilled spirits\u002Fliquor)\n11. Any other conditions or factors that, in the opinion of the investigator, may confound the efficacy or safety evaluation of the study, making the participant unsuitable for enrollment","40 Years",{"count":182,"type":22},38,[132],"This study is a 24-week, single-center, randomized, double-blind, sham-controlled, parallel-group clinical trial. A total of 38 patients with type 2 diabetes and mild cognitive impairment were enrolled and randomly assigned in a 1:1 ratio to either the treatment group (receiving active transcutaneous auricular vagus nerve stimulation) or the sham control group (receiving sham transcutaneous auricular vagus nerve stimulation). The primary objective of this study is to evaluate the potential disease-modifying effects of transcutaneous auricular vagus nerve stimulation on cognitive impairment in patients with type 2 diabetes.",[186,187],"Type 2 Diabetes","Mild Cognitive Impairment",[186,187,189,190],"Cognitive Impairment","Transcutaneous Auricular Vagus Nerve Stimulation",{"date":168,"type":34},{"date":193,"type":22},"2026-05-20",{"date":195,"type":22},"2027-12-31",{"name":39,"class":40},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":221,"locationsCount":222},"100643538","diagnostic-value-of-the-liver-inflammation-index-for-mash-in-patients-with-t2dm-and-mafld-100643538","NCT07632677","Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD","A Multicenter Cross-Sectional Study Evaluating the Diagnostic Accuracy of the Liver Inflammation Index for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Patients With Concurrent Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Adults aged ≥18 years, with no restrictions on sex;\n2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).\n\nExclusion Criteria:\n\n1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;\n2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases;\n3. History of hepatic decompensation;\n4. History of hepatectomy or liver transplantation;\n5. History of other malignancies;\n6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;\n7. History of transjugular intrahepatic portosystemic shunt (TIPS);\n8. Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels \\>5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF);\n9. Clinical or subclinical hypothyroidism or hyperthyroidism.",{"count":205,"type":22},10000,"This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).",[135,208,209],"MASH - Metabolic Dysfunction-Associated Steatohepatitis","Metabolic Dysfunction-associated Fatty Liver Disease",[211,212,213,214],"Type 2 Diabetes Mellitus","MASH","MAFLD","Liver inflammation index","2026-06-02",{"date":217,"type":34},"2026-06-08",{"date":219,"type":22},"2026-05-15",{"date":195,"type":22},{"name":39,"class":40},22,{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100640987","transcutaneous-auricular-vagus-nerve-stimulation-for-poor-weight-loss-response-to-lifestyle-intervention-100640987","NCT07630597","Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Lifestyle Intervention","Transcutaneous Auricular Vagus Nerve Stimulation as an Adjunctive Treatment for Overweight\u002FObese Patients With Poor Weight Loss Response to Lifestyle Intervention: A Single-Center, Randomized, Sham-Controlled Pilot Study","Inclusion Criteria:\n\n1. Completed 12 weeks of lifestyle intervention treatment with ≤5% weight loss during the treatment period;\n2. Completed 12 weeks of lifestyle intervention, with less than 1 month since completion, and achieved ≤5% weight loss during the intervention period;\n3. Current body mass index (BMI) ≥28 kg\u002Fm², or BMI ≥24 kg\u002Fm² with at least one weight-related comorbidity (e.g., hypertension or fatty liver disease);\n4. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of diseases that may substantially affect body weight homeostasis, including Cushing's syndrome, uncontrolled thyroid disease (thyroid-stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL), malignancy, or similar conditions;\n2. Use within the past 3 months of medications that may significantly affect body weight, including glucocorticoids and antipsychotic agents;\n3. Skin infection or damage involving the auricular area;\n4. Women planning pregnancy in the near future;\n5. Inability to complete the 12-week intervention period for practical reasons, such as frequent business travel or planned travel.","50 Years",{"count":232,"type":22},24,[132],"This single-center, randomized, single-blind, sham-controlled pilot study aims to evaluate the adjunctive effect of transcutaneous auricular vagus nerve stimulation (taVNS) in overweight\u002Fobese patients who show a poor weight loss response to lifestyle intervention. Participants who achieve no more than 5% weight loss after 12 weeks of lifestyle intervention will be randomized to receive either taVNS plus lifestyle intervention or sham stimulation plus lifestyle intervention for an additional 12 weeks. The primary objective is to compare the percent change in body weight from baseline between the two groups after 12 weeks of intervention. Secondary objectives include evaluation of changes in body composition and fat distribution, autonomic function, liver-related parameters, and glycemic and lipid-related metabolic parameters.",[236],"Obesity & Overweight",[236,190,238,239],"Lifestyle Intervention","Non-responders",{"date":241,"type":34},"2026-06-05",{"date":243,"type":34},"2026-05-08",{"date":245,"type":22},"2027-03-31",{"name":39,"class":40},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":230,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":41},"100640527","transcutaneous-auricular-vagus-nerve-stimulation-for-poor-weight-loss-response-to-incretin-receptor-agonists-100640527","NCT07619989","Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists","Adjunctive Transcutaneous Auricular Vagus Nerve Stimulation in Overweight or Obese Patients With a Suboptimal Weight-Loss Response to Incretin Receptor Agonists: A Single-Center, Randomized, Sham-Controlled Pilot Study","Inclusion Criteria:\n\n1. Individuals with obesity, or overweight accompanied by at least one weight-related comorbidity (e.g., hypertension or fatty liver disease), who have been receiving incretin receptor agonist therapy for at least 6 months and have achieved ≤10% weight loss during treatment;\n2. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of diseases that may substantially affect body weight homeostasis, including Cushing's syndrome, uncontrolled thyroid disease (thyroid-stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL), malignancy, or similar conditions;\n2. Use within the past 3 months of medications, other than incretin receptor agonists, that may significantly affect body weight, including glucocorticoids and antipsychotic agents;\n3. Skin infection or damage involving the auricular area;\n4. Women planning pregnancy in the near future;\n5. Contraindications to MRI, such as metallic prostheses or claustrophobia;\n6. Diagnosis of diabetes mellitus; Inability to complete the 12-week intervention period for practical reasons, such as frequent business travel or planned travel.",{"count":232,"type":22},[132],"This is a single-center, randomized, participant-blinded, sham-controlled pilot trial designed to evaluate the adjunctive effect of transcutaneous auricular vagus nerve stimulation (taVNS) in overweight or obese patients who show a suboptimal weight-loss response to incretin receptor agonist therapy. A total of 24 participants will be randomly assigned to receive either taVNS plus tirzepatide 5 mg or sham stimulation plus tirzepatide 5 mg for 12 weeks. The primary objective is to compare the percent change in body weight from baseline to week 12 between the two groups.",[236],[236,190,259,239],"Incretin Receptor Agonists","2026-05-28",{"date":215,"type":34},{"date":263,"type":34},"2026-04-21",{"date":265,"type":22},"2026-07-21",{"name":39,"class":40},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":41},"100638009","prophylactic-antibiotics-in-preventing-surgical-site-infection-after-hepatobiliary-surgery-in-high-resistant-settings-100638009","NCT07620223","Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings","Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings: A Randomized Clinical Trial","PASH","Inclusion Criteria:\n\n* Adult patients aged ≥18 years;\n* Deemed eligible for elective hepatobiliary surgery;\n* Demonstrated comprehension of the study nature and expressed willingness to comply with trial procedures;\n* Capable of providing written informed consent.\n\nExclusion Criteria:\n\n* History of β-lactam allergy or hypersensitivity\n* Uncontrolled preoperative infection;\n* Current or recent (within the preceding month) systemic corticosteroid administration;\n* Severe hepatic or renal impairment;\n* Pregnancy or lactation;\n* Concurrent enrolment in another clinical trial;\n* Any other condition deemed by the investigator to render the patient unsuitable for study participation.",{"count":276,"type":22},378,[132],"To analyse the efficacy of different preoperative prophylactic antimicrobial regimens for perioperative infection prevention in patients undergoing hepatobiliary surgery in a high antimicrobial resistance setting.",[280,281],"Hepatobiliary Surgery","Prophylactic Antibiotics",[280,283,284,285],"Antimicrobial resistance","Prophylactic antibiotic","Surgical site infection","2026-05-27",{"date":215,"type":34},{"date":289,"type":34},"2026-05-24",{"date":291,"type":22},"2029-01-31",{"name":39,"class":40},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":41},"100623664","diagnostic-accuracy-of-a-diquat-quantitative-detection-kit-and-a-portable-mass-spectrometry-system-for-quantifying-diquat-concentrations-in-human-blood-samples-100623664","NCT07399574","Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples","Accuracy, Safety, and Clinical Performance of a Diquat Quantitative Detection Kit (In-Situ Ionization Mass Spectrometry) and a Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples (Whole Blood\u002FPlasma)","Inclusion Criteria:\n\n1. Patients with suspected or clinically diagnosed acute diquat poisoning, providing whole blood and\u002For plasma samples, including qualified residual specimens retained after prior clinical testing when available.\n2. The participant or their legally authorized representative can fully understand the study purpose and procedures, voluntarily agrees to participate, and is willing and able to comply with the study requirements.\n3. Sample collection is performed according to routine clinical standards, with no apparent ethical concerns related to sample acquisition.\n\nExclusion Criteria:\n\n1. Abnormal sample appearance, such as visible flocculent material or other gross abnormalities.\n2. The participant is unable to provide a specimen, or the specimen does not meet testing requirements.\n3. Any participant considered inappropriate for inclusion by the investigator.",{"count":301,"type":22},60,"This is an observational, non-interventional diagnostic accuracy study designed to evaluate a diquat quantitative detection kit (ambient ionization mass spectrometry method) and a portable mass spectrometry analysis system for measuring diquat concentrations in human blood samples (whole blood\u002Fplasma), using LC-MS\u002FMS as the clinical gold standard for comparison.",[304],"Diquat Poisoning",{"date":286,"type":34},{"date":307,"type":22},"2026-09-01",{"date":37,"type":22},{"name":39,"class":40},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":4},"100610961","phase-1-accelerated-hemodiafiltration-in-severe-acute-diquat-ahead-poisoning-100610961","NCT07234383","Accelerated HEmodiafiltration in Severe Acute Diquat (AHEAD) Poisoning","Accelerated HEmodiafiltration in Severe Acute Diquat (AHEAD) Poisoning: a Single-center, Single-arm, Open-label, Clinical Trial","Inclusion criteria:\n\n1. Age ≥ 18 years; and\n2. A history of oral exposure to diquat solution, reported by patient(s) or their legal proxies; and\n3. An exposure time (time form exposure to presentation at ED) ≤ 48 hours, reported by patient(s) or their legal proxies; and\n4. Plasma diquat concentration measured upon ED presentation ≥ 1,000 ng\u002FmL.\n\nExclusion criteria:\n\n1. Evidence of co-ingestion of other toxic substances alongside diquat; and\u002For\n2. Withholding of CVVHDF due to limitations on the escalation of life-sustaining therapies; and\u002For\n3. Any CKRT within the previous 2 months; and\u002For\n4. Kidney transplant within the past 365 days; and\u002For\n5. Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate calculated using serum creatine (eGFRer) of less than 30 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, if pre-hospitalization serum creatine is available; and\u002For (6) Treating clinician(s) believe(s) that either immediate or deferral of CVVHDF initiation is mandated; and\u002For (7) Pregnant or breast feeding.",{"count":232,"type":22},[101],"Diquat (1,1'-ethylene-2,2'-bipyridinium) is a bipyridine herbicide that shares a similar physicochemical structure and redox cycling mechanism with paraquat. Upon ingestion, it is rapidly absorbed and distributes widely, including gastrointestinal tract, kidneys, liver, skeletal muscle, lungs, myocardium, and central nervous system. Severe diquat poisoning commonly causes toxic encephalopathy, circulatory collapse, and multiorgan dysfunction. Extracorporeal treatments, including hemoperfusion, hemodialysis, and continuous kidney replacement therapy, are frequently used in management. Continuous veno-venous hemodiafiltration (CVVHDF), the most frequently used continuous kidney replacement therapy modality, is primarily indicated for acute kidney injury. Acute kidney injury occurs in up to 73.3% of patients with acute diquat poisoning, and nearly all patients with severe acute diquat poisoning are at risk of developing acute kidney injury. In clinical practice, patients with severe acute diquat poisoning are typically defined as those with a plasma diquat concentration of ≥1000 ng\u002FmL measured at the time of presentation to the emergency department. However, the Extracorporeal Treatments in Poisoning (EXTRIP) workgroup has not issued any definitive recommendations on initiating extracorporeal treatments for diquat poisoning, and the optimal timing for starting CVVHDF has not been evaluated in clinical trials. Current practice typically delays CVVHDF until acute kidney injury occurs. A preliminary retrospective cohort study suggested that, among severe acute diquat poisoning patients treated with combined hemoperfusion and CVVHDF, an interval of \\\u003C30 minutes between hemoperfusion and CVVHDF was associated with a significantly lower risk of death compared with longer intervals (≥30 minutes). Accordingly, this study proposes a single-arm trial (SAT) to determine whether accelerated initiation of CVVHDF immediately following hemoperfusion improves outcomes in patients with severe acute diquat poisoning.",[304],{"date":286,"type":34},{"date":323,"type":22},"2027-01-01",{"date":325,"type":22},"2030-12-31",{"name":39,"class":40},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":348,"locationsCount":349},"100638206","multicenter-validation-of-a-risk-prediction-model-for-mdrgnb-infection-100638206","NCT07603128","Multicenter Validation of a Risk Prediction Model for MDRGNB Infection","Prospective Validation of a Risk Prediction Model for MDRGNB Infection: A Multicenter Real-World Prospective Study","PRIOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* ICU stay ≥48 hours;\n* At least one clinical microbiological specimen collected and submitted for testing within 48 hours of ICU admission, with the first submission time designated as the index time;\n* Core predictive variables of the model extractable from electronic medical records or laboratory information systems.\n\nExclusion Criteria:\n\n* For patients with multiple ICU admissions, only the first ICU stay was retained;\n* Missing or indeterminate primary outcome;\n* Missing key predictive variables that could not be handled according to prespecified rules.",{"count":336,"type":22},1000,"This prospective multicenter validation study aimed to evaluate the predictive performance of a previously developed model for MDRGNB infection in ICU patients.",[339],"Infection",[341,342,343,339],"Prediction model","MDRGNB","ICU","2026-05-22",{"date":286,"type":34},{"date":344,"type":34},{"date":37,"type":22},{"name":39,"class":40},11,{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":41},"100639557","clinical-efficacy-and-population-pharmacokinetics-of--lactams-in-cirrhotic-patients-100639557","NCT07612163","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Patients With Liver Cirrhosis: A Retro-prospective Observational Study","Inclusion Criteria:\n\nAge over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy\n\nExclusion Criteria:\n\nDuration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams",{"count":336,"type":22},"Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.",[360],"Bacterial Infections",[362,360,363],"β-lactam","Liver cirrhosis","2026-05-21",{"date":260,"type":34},{"date":367,"type":34},"2023-12-31",{"date":195,"type":22},{"name":39,"class":40},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":49,"minAge":377,"maxAge":19,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":4},"100638598","structural-mechanisms-of-dual-target-tdcs-in-stroke-hemiparetic-hand-100638598","NCT07605039","Structural Mechanisms of Dual-Target tDCS in Stroke Hemiparetic Hand","Multimodal MRI-Based Study of the Structural Mechanisms Underlying Interhemispheric Network Reorganization Induced by Dual-Target tDCS in Stroke Hemiparetic Hand","Inclusion Criteria:\n\n1. Diagnosed with stroke according to the \"Diagnostic Criteria for Major Cerebrovascular Diseases in China, 2019\", confirmed by cranial CT or MRI.\n2. First-ever unilateral subcortical stroke (involving the corona radiata, basal ganglia, thalamus, internal capsule, etc.).\n3. Age 30-75 years.\n4. Right-handed prior to stroke onset.\n5. Stroke onset ≥ 2 weeks.\n6. Hemiplegic hand function at Brunnstrom Stage I-III.\n7. Written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Any contraindications to MRI.\n2. History of other neurological disorders or substance abuse.\n3. Unstable conditions or rapidly progressive\u002Fmalignant diseases, e.g., severe atrial fibrillation.\n4. Severe skin allergies.\n5. Inability to cooperate with basic communication or assessments, such as severe aphasia.","30 Years",{"count":379,"type":22},56,[132],"This is a single-center, randomized, single-blind study investigating the effects of dual-target transcranial direct current stimulation (tDCS) combined with task-oriented functional electrical stimulation on upper limb recovery in patients with non-acute post-stroke hemiplegia. A total of 56 participants will be recruited and randomly assigned (1:1) to the dual M1 tDCS group or sham stimulation group. The intervention is delivered five times per week for four weeks, with 20 sessions in total. Multimodal MRI (T1W, T2W, and DTI) will be used to assess structural and network-level reorganization of sensorimotor pathways, including the corticospinal tract, in response to tDCS.\n\nThe primary outcome is the Broetz hand function score, evaluated at baseline, post-intervention, and six-month follow-up. Secondary outcomes include Fugl-Meyer Assessment of the upper extremity (FMA-UE) and multimodal MRI-derived measures of white matter integrity. This study aims to elucidate the structural constraints underlying sensorimotor network lateralization and to identify responder and non-responder profiles based on corticospinal tract damage, providing mechanistic insight into individualized tDCS-based neurorehabilitation after stroke.",[383],"Stroke","2026-05-17",{"date":344,"type":34},{"date":387,"type":22},"2026-05-06",{"date":37,"type":22},{"name":39,"class":40},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":398,"sex":49,"minAge":18,"maxAge":399,"enrollmentInfo":400,"targetDuration":402,"studyType":158,"phases":4,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":41},"100633888","a-machine-learning-based-risk-prediction-model-for-head-and-neck-cancerous-lesions-100633888","NCT07532538","A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions","A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions: A Multidimensional Feature Study Integrating Demographics and Clinical Symptomatology","ML-HNC-Risk","Inclusion Criteria:\n\nAge ≥ 18 years old. Patients with complete clinical data information and laryngoscopic images.\n\nExclusion Criteria:\n\nRefusal to sign the informed consent form. Incomplete clinical data. Known diagnosis of other head and neck malignancies (thyroid cancer, malignant parotid tumors, etc.",true,"100 Years",{"count":401,"type":22},3000,"6 Months","This study aims to develop and validate a clinical prediction model for the risk of head and neck cancerous lesions using deep learning combined with AI algorithms, based on multi-center clinical data.",[405,406,407],"Hypopharyngeal Cancer","Laryngeal Cancer","Head and Neck Cancer",[409,410,411,412,413,414],"Head and neck malignant lesions","Hypopharyngeal cancer","Laryngeal cancer","AI","machine learning","AI-assisted diagnosis","2026-04-12",{"date":417,"type":34},"2026-04-16",{"date":419,"type":22},"2026-04-30",{"date":421,"type":22},"2030-11-30",{"name":39,"class":40},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":19,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":41},"100620132","phase-1-kras-neoantigen-nanovaccine-as-adjuvant-therapy-for-colorectal-cancerpancreatic-cancer-100620132","NCT07353645","KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer\u002FPancreatic Cancer","Phase I\u002FII Clinical Study of KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer\u002FPancreatic Cancer With High Risk of Recurrence","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years, with an ECOG performance status of 0-1.\n* Patients with histologically confirmed colorectal adenocarcinoma or pancreatic adenocarcinoma who have undergone radical resection (R0) and completed at least 4 cycles of postoperative adjuvant chemotherapy.\n* Postoperative pathological stage for colorectal cancer is IIIA, IIIB, or IIIC. For pancreatic cancer, postoperative pathological stage is I, II, or III. The tumor must harbor at least one of the following KRAS hotspot mutations: G12D, G12V, G12R, G12A, G12S, G12C, or G13D.\n* No radiological evidence of tumor recurrence or metastasis.\n* Patients must meet the following hematologic criteria: Lymphocyte count ≥0.5×10⁹\u002FL, neutrophil count ≥1.5×10⁹\u002FL, white blood cell count \\>2.5×10⁹\u002FL; Hemoglobin ≥90 g\u002FL; Platelet count ≥90×10⁹\u002FL.\n* Patients must meet the following biochemical criteria: Total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤1.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance ≥30 mL\u002Fmin.\n* Patients must meet the following coagulation criteria: INR or PTT ≤1.5 × ULN.\n* Patients of childbearing potential must employ adequate contraception or other birth control methods before enrollment and throughout the trial.\n* Signed informed consent form has been obtained.\n* Ability to comply with the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\n* Patients with colorectal cancer exhibiting microsatellite instability-high (MSI-H)\u002Fdeficient mismatch repair (dMMR) or harboring BRAF mutations.\n* Pancreatic cancer patients with neuroendocrine tumor components are excluded.\n* Patients with a history of other malignancies, except for carcinoma in situ of the cervix, treated squamous cell carcinoma or bladder epithelial tumors (Ta and TIS), or other malignancies that have been curatively treated (at least 5 years prior to enrollment).\n* Prior treatment with anticancer vaccines or any antibodies targeting T-cell co-regulatory proteins (e.g., anti-PD1, anti-PDL1, or anti-CTLA4).\n* Patients with HIV, HCV, or HBV infection; uncontrolled coronary artery disease or asthma; uncontrolled cerebrovascular disease; or any other condition deemed by the investigator as grounds for exclusion.\n* Patients who are on immunosuppressants or systemic corticosteroid therapy for immunosuppressive purposes (at a dose \\>10 mg\u002Fday prednisone or equivalent) and have continued use within 2 weeks prior to enrollment.\n* Poorly controlled cardiac clinical symptoms or diseases, such as: Heart failure of NYHA Class II or higher; Unstable angina; Myocardial infarction within the past year; Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; QTc \\>450 ms (males); QTc \\>470 ms (females).\n* Abnormal coagulation function (INR \\>2.0, PT \\>16 s), bleeding tendency, or current thrombolytic or anticoagulant therapy. Prophylactic use of low-dose aspirin or low molecular weight heparin is allowed.\n* Patients with active infection; unexplained fever ≥38.5°C within 7 days prior to medication; baseline white blood cell count \\>15×10⁹\u002FL; or suppurative and chronic infections with non-healing wounds.\n* Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.\n* Substance abuse, or clinical, psychological, or social factors that may affect the provision of informed consent or the conduct of the study.\n* Known or suspected allergy to drugs used in immunotherapy.\n* Inability to undergo immunological and clinical follow-up assessments.\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participation in other interventional drug clinical trials concurrently.",{"count":431,"type":22},49,[101,102],"This clinical trial will utilize a neoantigen nanovaccine constructed from the bacterial membranes of an engineered Lactococcus lactis strain (FOLactis). This platform, independently developed by our center, expresses KRAS antigenic peptides. The vaccine will be administered as adjuvant therapy to post-operative patients with colorectal or pancreatic cancer who carry KRAS mutations and are at high risk of recurrence. The study aims to assess the safety, immunogenicity, and preliminary efficacy of this neoantigen nanovaccine in a clinical setting.",[435,436],"Colorectal Cancer","Pancreatic Cancer","2026-04-10",{"date":439,"type":34},"2026-04-15",{"date":441,"type":34},"2026-03-23",{"date":443,"type":22},"2031-01-01",{"name":39,"class":40},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":453,"studyType":158,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":465,"locationsCount":41},"100581952","early-evaluation-of-exosome-multiomics-and-clinical-prognosis-in-patients-with-sudden-death-100581952","NCT06856993","Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death","Inclusion Criteria:\n\n* The death event happens suddenly.\n* Age ≥ 18 years\n* The patient had obvious clinical symptoms 24 hours before treatment\n* Life expectancy exceeds 3 days\n* Proxy of patients signs the informed consent form\n* Comply with ACS diagnostic indicators recommended by ACC \u002F AHA guidelines in 2016\n\nExclusion Criteria:\n\n* Death caused by accident, such as trauma, poisoning, etc.\n* Death from accidental or intentional overdose\n* Death from asphyxia\n* Death is caused by chronic disease or terminal illness\n* The patient died naturally\n* Has participated in other clinical studies\n* Immediate family members give up continuing treatment",{"count":452,"type":22},300,"3 Months","Acute coronary syndrome (ACS) is one of the main causes of death. Worldwide, tens of millions of patients are hospitalized for coronary heart disease and ACS every year. ACS may show acute myocardial infarction, unstable angina pectoris, and even induce early arrhythmia, leading to sudden death. Sudden cardiac death (SCD) has a strong correlation with ACS. Data from clinical and autopsy studies and death certificates show that 62-85% of patients with out of hospital SCD have a history of ACS, 10% have other cardiac structural abnormalities, and 5% have no cardiac structural abnormalities. An SCD surveillance study from Ireland concluded that most cases occurred in families, and the successful recovery of SCD was mainly related to ventricular fibrillation with arrhythmia. At present, there are few reports on the clinical and prognosis of ACS in China, and there is no guideline or consensus on the prevention and treatment of ACS patients. Known domestic research results show that the proportion of male, overweight \u002F obese, smokers in young ACS patients is higher than that in the elderly group, while the proportion of patients with hypertension, diabetes and cerebrovascular diseases is less than that of the elderly group. The levels of TC, TG, LDL-C and UA and the proportion of low HDL-C in young ACS patients were higher than those in elderly patients; The diagnosis of STEMI was the highest in the young ACS group, while the diagnosis of unstable angina pectoris was the most common in the elderly ACS group. The clinical manifestations of ACS vary greatly. 3% \\~ 5% of patients who exclude ACS only through myocardial markers, clinical blood transfusion and ECG still have myocardial infarction (MI). For the emergency department, early prediction of the risk of SCD in ACS patients and timely and accurate screening of high-risk patients are very important.",[456,457,458],"Sudden Cardiac Death","Exosome Multiomics","Clinical Prognosis","2026-04-06",{"date":461,"type":34},"2026-04-08",{"date":463,"type":34},"2021-12-22",{"date":195,"type":22},{"name":39,"class":40},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":128,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":41},"100632511","phase-2-safety-and-efficacy-of-anricfen-for-postoperative-analgesia-and-rehabilitation-promotion-after-pancreaticoduodenectomyintervention-measures-for-normal-adults-administer-ariceptin-injection-intravenously-post-operation-at-a-dose-of-1-gkgevery-8-hours-for-three-consecutive-days-after-surgery-100632511","NCT07514637","Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg\u002FKgevery 8 Hours for Three Consecutive Days After Surgery.","The Safety and Efficacy of Aniracetamfen for Postoperative Analgesia and Rehabilitation After Pancreaticoduodenectomy: A Single-center, Single-arm Clinical Study","Inclusion Criteria:\n\n* Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)\n* Age ≥ 18 years old and \\\u003C 80 years old\n* ASA Ⅰ-Ⅲ\n* Be able to clearly understand and voluntarily participate in the research\n\nExclusion Criteria:\n\n* Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system\n* History of long-term use of psychotropic drugs and cognitive dysfunction\n* Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system\n* Pregnancy or lactation period\n* History of allergy to NSAIDs, opioids, or to the test medication\n* Drug users, alcoholics, and opiate abusers\n* Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and\u002For sedatives\n* Those who had thyroid dysfunction before the operation",{"count":474,"type":22},35,[102],"Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.\n\nMain objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.\n\nSecondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.\n\nExploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.",[478],"Patients Who Undergo Pancreaticoduodenectomy",[480,481,482,483],"pancreaticoduodenectomy","Peripheral κ receptor agonist","analgesia","Promote recovery","2026-04-01",{"date":486,"type":34},"2026-04-07",{"date":488,"type":34},"2025-11-25",{"date":490,"type":22},"2026-03-31",{"name":39,"class":40},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":49,"minAge":230,"maxAge":19,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":518},"100599335","phase-3-glp-1gcg-dual-agonist-in-type-2-diabetes-with-early-dementia-light-cog-study-100599335","NCT07083154","GLP-1\u002FGCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","Efficacy, Safety, and Tolerability of a GLP-1\u002FGCG Dual Receptor Agonist in Type 2 Diabetes With Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus (T2DM).\n2. Aged 50-75 years (inclusive), male or female.\n3. Early symptomatic dementia (Mild cognitive impairment or mild dementia), defined as:\n\n   1. MMSE score \\>20 and \\\u003C27,\n   2. CDR global score 0.5-1.0 (inclusive), with a CDR memory subscore ≥0.5,\n   3. Subjective memory complaints for ≥6 months.\n4. Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:\n\n   1. Lifestyle\u002Fdietary intervention alone (no glucose-lowering drugs),\n   2. Oral antidiabetic drugs (OADs), with or without once-daily basal insulin.\n5. HbA1c 7.0-9.0% (inclusive) at screening.\n6. BMI ≥20 kg\u002Fm², with stable weight (fluctuation \\\u003C5%) for ≥3 months.\n7. Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:\n\n   1. No treatment: Not receiving any pharmacological or non-pharmacological interventions for cognitive impairment;\n   2. Non-pharmacological therapy only: Engaged exclusively in non-drug interventions (e.g., cognitive training);\n   3. Pharmacological therapy: Using approved symptomatic cognitive-enhancing medications (e.g., cholinesterase inhibitors, NMDA receptor antagonists), excluding disease-modifying therapies for Alzheimer's disease (AD).\n8. Ability to comply with systematic cognitive and functional assessments.\n9. Fully understands the trial protocol, voluntarily signs the informed consent form (ICF), and agrees to adhere to all study requirements and restrictions.\n\nExclusion Criteria:\n\n1. Evidence of other neurodegenerative diseases that may affect cognition, excluding Alzheimer's disease, including:\n\n   1. Frontotemporal dementia (FTD) and its variants\n   2. Parkinson's disease (PD), dementia with Lewy bodies (DLB)\n   3. Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD)\n   4. Multiple system atrophy (MSA), multiple sclerosis (MS), Huntington's disease (HD), etc.\n2. Current diagnosis of a poorly controlled or unstable psychiatric disorder (including but not limited to schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders, etc.), which, in the investigator's judgment, may interfere with study assessments, affect treatment compliance, or increase participant risk.\n3. With a Patient Health Questionnaire-9 (PHQ-9) score ≥10 at screening, or a Generalized Anxiety Disorder Scale-7 (GAD-7) score ≥10 at screening.\n4. History of stroke (ischemic\u002Fhemorrhagic), transient ischemic attack (TIA), or epileptic seizure within 3 months prior to screening; Current or prior diagnosis of central nervous system (CNS) disorders that may impair cognitive function, including but not limited to:\n\n   CNS infections, Intracranial tumors, Metabolic encephalopathy, Neurological disorders due to malnutrition, or Severe traumatic brain injury.\n5. Acute hyperglycemic\u002Fhypoglycemic events within 1 year, including: Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and Hypoglycemic coma\n6. Use of GLP-1R agonists, GLP-1R\u002FGIPR dual agonists, or GLP-1R\u002FGCGR dual agonists within 3 months prior to screening.\n7. Regular use (\\>2 doses\u002Fweek) of moderate-to-strong anticholinergic drugs within 4 weeks prior to screening; Use within 3 months prior to screening of: Anti-Parkinsonian drugs, Antiepileptic drugs, Antipsychotics, Morphine and opioid analgesics (Exemption: Short-term use \\[\\\u003C5 days\\] for surgery\u002Facute injury, if completed \\>4 weeks before screening); Use within 4 weeks prior to screening of: CNS stimulants; Medical\u002Frecreational cannabis, cannabinoids, or cannabidiol (CBD).a. Moderate\u002Fhigh anticholinergics, antiparkinsonian\u002Fantiepileptic drugs.\n8. Alcohol abuse (defined as \\>21 units\u002Fweek for men or \\>14 units\u002Fweek for women; 1 unit = 360 mL beer, 150 mL wine, or 45 mL spirits).\n9. Medical history of:\n\n   1. Medullary thyroid carcinoma (MTC), pancreatitis\n   2. Multiple endocrine neoplasia type 2 (MEN2)\n   3. Gallbladder\u002Fbiliary disease, severe gastrointestinal disorders, or bowel resection\n   4. Active malignancy\n10. Uncontrolled or potentially unstable diabetic retinopathy\u002Fmaculopathy.\n11. Severe organ dysfunction, including:\n\n    1. ALT\u002FAST \\>3× upper limit of normal (ULN)\n    2. eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² (CKD-EPI equation)\n    3. Unstable angina, myocardial infarction (MI), or NYHA Class II+ heart failure within 3 months\n12. Known\u002Fsuspected hypersensitivity to the investigational product or related compounds\n13. Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.\n14. MRI contraindications (e.g., metal implants, claustrophobia).\n15. Participation in other clinical trials within 3 months, involving an investigational medicinal product or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study.\n16. Any other condition deemed by the investigator to compromise safety or interfere with study assessments.",{"count":500,"type":22},420,[76],"The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.",[504,187,186],"Dementia, Mild",[186,506,187,507,508,509],"Mild Dementia","GLP-1\u002FGCG Dual Agonist","Cognitive Dysfunction","Early Dementia","2026-03-03",{"date":512,"type":34},"2026-03-05",{"date":514,"type":34},"2025-09-27",{"date":516,"type":22},"2029-08-01",{"name":39,"class":40},8,{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":533,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":41},"100553306","a-multicenter-randomlzed-controlled-umbrella-trial-for-minimally-invasive-neurosurgery-with-al-assisted-robotic-guidance-for-hemorrhagic-stroke-large-basal-ganglia-hemorrhage-100553306","NCT06484374","A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage","RAINBOW-LBH","Inclusion Criteria:\n\n1. Age ≥18 years at randomization;\n2. Diagnosed with hypertensive basal ganglia hemorrhage via imaging (CT, CTA, etc.);\n3. Hematoma volume ≥30 mL prior to randomization;\n4. Glasgow Coma Scale (GCS) score ≥ 5;\n5. Available for surgery within 72 hours after onset;\n6. Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage;\n7. Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements.\n\nExclusion Criteria:\n\n1. Hematoma involving the thalamus (volume \\>5 mL or diameter \\>2 cm), midbrain, or ventricles (Graeb score ≥3), or other locations;\n2. Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage;\n3. Signs of impending herniation such as midline shift exceeding 1 cm or ipsilateral pupillary changes;\n4. Any irreversible coagulation disorder or known coagulopathy; platelet count \\\u003C100,000; INR \\>1.4; or use of anticoagulant medication within 7 days before the current hemorrhage;\n5. Current or probable pregnancy;\n6. Patients with concurrent severe illness likely to influence outcome assessment;\n7. Difficulty in follow-up or poor compliance due to any cause.",{"count":527,"type":22},198,[132],"This substudy is a prospective, multicenter, parallel-controlled, randomized controlled trial designed to evaluate whether robot-assisted endoscopic evacuation of large basal ganglia hematomas can improve patient outcomes compared with traditional surgical approaches such as small craniotomy or large-bone-flap intracranial hematoma evacuation.",[531,532],"Hematoma Brain","Large Basal Ganglia Hemorrhage",[532,534,535,536,537,538],"Al-assisted robotic guidance","multicenter","Randomlzed","controlled","umbrella trial","2026-02-12",{"date":541,"type":34},"2026-02-17",{"date":543,"type":34},"2025-12-20",{"date":195,"type":22},{"name":39,"class":40},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":555,"studyType":158,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":4},"100623933","validating-fish-oils-role-in-alleviating-bortezomib-induced-neuropathy-a-multi-method-study-integrating-big-data-experimental-and-clinical-research-100623933","NCT07403071","Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research","A Study Combining Big Data Mining With Experimental and Clinical Research to Validate the Alleviating Effect of Fish Oil on Bortezomib-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* (1) Aged 18 years or older, regardless of gender. (2) Diagnosed with multiple myeloma (MM) according to the \"Guidelines for the Diagnosis and Management of Multiple Myeloma,\" and scheduled to receive bortezomib as first-line therapy.\n\n  (3) Absence of baseline peripheral neuropathy prior to the initiation of bortezomib treatment.\n\n  (4) Provision of signed informed consent.\n\nExclusion Criteria:\n\n* (1) Patients with poor medication adherence. (2) Women who are pregnant or lactating. (3) Cases deemed ineligible by the investigator.",{"count":554,"type":22},200,"24 Months","The goal of this study is to find out if taking fish oil by mouth can help prevent or lessen a side effect called peripheral neuropathy in patients who are being treated with the chemotherapy drug bortezomib.\n\nWe are mainly looking to answer one question: Can fish oil reduce the chances of getting this nerve damage, or make it less severe, for these patients?",[558,559],"Multiple Myeloma","Peripheral Neuropathy Due to Chemotherapy","2026-02-04",{"date":562,"type":34},"2026-02-11",{"date":564,"type":22},"2026-05-01",{"date":195,"type":22},{"name":39,"class":40},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":586},"100594724","multicenter-prospective-observational-study-on-the-treatment-of-type-2-diabetes-with-proline-plus-empagliflozin-tablets-100594724","NCT07023172","Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets","Inclusion Criteria:\n\n* 1.Age ≥18 years, regardless of gender. 2.Clinically diagnosed with type 2 diabetes mellitus (per the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus \\[2020 Edition\\]).\n\n  3.Deemed suitable by the investigator for treatment with proline-containing gliflozin tablets (Hui You Jing) and being prescribed this medication for the first time.\n\n  4.Availability of glycated hemoglobin (HbA1c) test results within 4 weeks prior to enrollment.\n\n  5.Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n\\- 1.History of moderate to severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²), end-stage renal disease, or dialysis.\n\n2.Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Severe allergy to gliflozin or any excipient of the study drug. 3.Current or recent (within 1 month) participation in any other clinical trial. 4.Investigator judgment of unsuitability for the study.",{"count":401,"type":22},"This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.",[186],[577,578],"Type 2 diabetes","Proline plus empagliflozin tablets",{"date":580,"type":34},"2026-02-05",{"date":582,"type":34},"2025-05-30",{"date":584,"type":22},"2027-10",{"name":39,"class":40},2,{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":19,"enrollmentInfo":594,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":41},"100566963","phase-2-nal-iri5-fulv-chemotherapy-combined-with-pd-l1-inhibitor-and-multi-target-anti-angiogenic-small-moleculesbrt-as-second-line-therapy-in-metastatic-pancreatic-cancer-patients-100566963","NCT06662006","Nal-IRI\u002F5-FU\u002FLV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","Efficacy and Safety of Second-line Therapy by Nal-IRI\u002F5-FU\u002FLV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT in Metastatic Pancreatic Cancer Patients: a Prospective, Multicentre, Single-arm, Multi-cohort Study","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 75 years, ECOG score of ≤2 points, expected survival time ≥ 3 months.\n2. Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer.\n3. Imaging suggests distant measurable lesions.\n4. Failure of first-line therapy and no use of fluorouracil, irinotecan, or liposomal irinotecan drugs in the first-line therapy.\n\nPatients need to meet the following hematologic indicators e1. Neutrophil count ≥ 1.5×109\u002FL e2. Hemoglobin ≥ 10 g\u002FdL e3. Platelet count ≥ 100×109\u002FL f. Patients need to meet the following biochemical parameters f1. Total bilirubin ≤ 1.5× upper limit of normal (ULN) f2. AST and ALT \\<1.5×ULN f3. Creatinine clearance ≥ 60ml\u002Fmin g. Patients of childbearing age need to take appropriate protective measures (contraception or other methods of birth control) before enrollment and during the trial.\n\nH. Has signed an informed consent form. i. Able to follow the study protocol and follow-up process.\n\nExclusion Criteria:\n\n1. Have received second-line or more anti-tumor therapy in the past.\n2. First-line treatment with fluorouracil, irinotecan or liposomal irinotecan, etc.\n3. Patient has a prior history of other tumors, unless it is cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumors (Ta and TIS) or other malignancies that have received curative therapy (at least more than 5 years prior to enrollment).\n4. Patient has an active bacterial or fungal infection (≥ 3rd edition NCI-CTC2 grade).\n\nPatient has HIV, HCV, HBV infection, uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease or other disease deemed non-enrollable by the investigator.\n\nf. Patients with autoimmune diseases or immunodeficiencies who should be treated with immunosuppressive drugs.\n\ng. Pregnant and lactating women. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.\n\nh. Substance abuse, clinical or psychological, or social factors that compromise informed consent or study conduct.\n\ni. Those who may be allergic to treatment drugs.",{"count":379,"type":22},[102],"This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator.\n\nThe indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be assigned to liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)\u002Fleucovorin (LV) (nal-IRI\u002F5-FU\u002FLV) combined with benmelstobart and anlotinib ± SBRT.\n\nThe total sample size for this study is expected to be 56 subjects.",[598],"Advanced Metastatic Pancreatic Cancer",[600,601,602,603],"pancreatic cancer","liposomal irinotecan","benmelstobart","anlotinib",{"date":605,"type":34},"2026-02-06",{"date":607,"type":34},"2024-03-01",{"date":609,"type":22},"2027-12",{"name":39,"class":40},""]